Data presented here demonstrate that ALDH1A3 is expressed and predicts worse outcomes in multiple cancer types that do not respond to immune checkpoint inhibitors, suggesting that therapeutic targeting of ALDH1A3 is a compelling strategy in anti-PD-1-resistant cancers. The gene discussed is ALDH1A3; the disease is cancer.